Last reviewed · How we verify
NCT06806059: PRACTICE
Preoperative Physical Activity Before Radical Cystectomy and the Impact on Morbidity
NA trial testing Physical Activity in Urothelial Carcinoma Bladder in 146 participants. Currently enrolling.
29 November 2026
Quick facts
| Lead sponsor | Ludwig-Maximilians - University of Munich |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 146 |
| Start date | 29 November 2024 |
| Primary completion | 29 November 2026 |
| Estimated completion | 29 November 2027 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Physical Activity
Conditions studied
- Urothelial Carcinoma Bladder — all drugs for Urothelial Carcinoma Bladder →
Sponsor
Ludwig-Maximilians - University of Munich
Who can join
18 and older, any sex, with Urothelial Carcinoma Bladder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Bladder cancer (BC) is the 6th most common tumor in Europe, with over 540,000 new cases globally each year. While 75% of cases are non-muscle-invasive and treated bladder-preservingly, muscle-invasive, non-metastatic BC requires radical cystectomy (RC), often with neoadjuvant chemotherapy. RC has one of the highest complication rates in urology, and rehabilitation focuses on mitigating functional impairments, restoring physical and mental capacity, and enabling a swift return to daily life. The ERAS (Enhanced Recovery After Surgery) protocol has shown benefits in reducing hospital stays without increasing complications in RC. Prehabilitation studies in cancer patients have demonstrated improvements in strength and fitness, though without significant reductions in complications or mortality. This prospective randomized study, conducted over three years at the University of Munich, will evaluate the effect of preoperative physical activity on perioperative morbidity (primary endpoint). Secondary endpoints include quality of life, hospital stay, mortality, and postoperative physical activity. The intervention group will target 8,000-10,000 daily steps for four weeks preoperatively, monitored via pedometers. Follow-ups will assess physical activity and quality of life at specific intervals pre- and post-surgery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Abstracts selected for poster presentation [listed in alphabetical order by presenter].
· 2026 · PMID 41625014 · DOI 10.1177/23523735251412131
Verify or expand the search:
- PubMed search for NCT06806059
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Physical Activity
Trials testing the same drug.
- NCT07480811 — The Effect of the DASH Diet on Clinical and Metabolic Parameters in Children With MASLD · NA · not yet recruiting
- NCT07125053 — COPD Resources, Education, and Activity Designed for You Study · NA · recruiting
- NCT07099040 — Community-based Multi-domain Intervention to Detect and Delay Cognitive Decline in Community-dwelling Older Adults: A Pi · NA · not yet recruiting
- NCT06948500 — Effectiveness of an IVR-based Therapeutic Exercise Program With Altered Visual Feedback in Fibromyalgia Patients · NA · recruiting
- NCT06822387 — Health Without Barriers/Salud Sin Barreras- Northern Colorado · NA · recruiting
Other recruiting trials for Urothelial Carcinoma Bladder
Currently open trials in the same condition.
- NCT03185468 — Intervention of Bladder Cancer by CAR-T · Phase 1, PHASE2 · recruiting
- NCT06983210 — Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma · Phase 2 · recruiting
- NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
- NCT06444815 — A Study of VET3-TGI in Patients With Solid Tumors · Phase 1 · recruiting
- NCT05241340 — Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer · Phase 2 · active not recruiting
Other Ludwig-Maximilians - University of Munich trials
Trials by the same sponsor.
- NCT07514520 — Decision-making, Ethical Consent, and Interactive Dialogue in Ongoing Neurocognitive Decline - DECISION · active not recruiting
- NCT07504965 — Dementia-friendly Apothecaries as a Resource for Mental Heath in the Elderly · recruiting
- NCT07100548 — A Qualitative Analysis of Youth Responses to Depression Education Delivered on Social Media · completed
- NCT07061600 — Enhancing Depression Literacy and Reducing Stigma in Adolescents Through Social Media · NA · completed
- NCT06749106 — Plaque Imaging in Routine Care to Detect Intraplaque Hemorrhage · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06806059 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ludwig-Maximilians - University of Munich
- Last refreshed: 3 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06806059.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing